← Back to Search

Glucagon-like peptide-1 (GLP-1) receptor agonist

Tirzepatide for Obesity

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 18

Summary

This trial tests tirzepatide in people with obesity to see how it affects calorie burning and food intake. The study lasts several months and involves multiple visits to the study center. Tirzepatide is a new treatment effective in managing obesity and type 2 diabetes.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 18
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 18 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
Secondary study objectives
Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)
Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)
Change From Baseline to Week 18 in Body Fat Mass
+12 more

Side effects data

From 2022 Phase 3 trial • 210 Patients • NCT05024032
40%
Diarrhoea
30%
Nausea
27%
Decreased appetite
23%
Upper respiratory tract infection
19%
Abdominal distension
11%
Vomiting
11%
Gastroenteritis
9%
Flatulence
9%
Abortion induced
7%
Abdominal pain upper
7%
Gingivitis
7%
Amylase increased
7%
Lipase increased
6%
Abdominal pain
6%
Injection site reaction
6%
Menstruation irregular
4%
Hepatic function abnormal
4%
Hyperuricaemia
3%
Uterine polyp
3%
Vaginal infection
3%
Dizziness
1%
Hand fracture
1%
Supraventricular tachycardia
1%
Hiccups
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
10 mg Tirzepatide
15 mg Tirzepatide

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 15 Milligram (mg) TirzepatideExperimental Treatment1 Intervention
Participants received 15 mg of tirzepatide QW by SC injection.
Group II: PlaceboPlacebo Group1 Intervention
Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tirzepatide
2019
Completed Phase 3
~7520

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,672 Previous Clinical Trials
3,463,738 Total Patients Enrolled
70 Trials studying Obesity
55,592 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,386 Previous Clinical Trials
426,643 Total Patients Enrolled
52 Trials studying Obesity
35,134 Patients Enrolled for Obesity
~10 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top